We thus conducted a longitudinal study on a dual-center cohort of newly diagnosed, untreated PD patients (“de novo”) with a baseline assessment of amyloid peptides, tau proteins, and α-syn CSF levels to estimate the association between the CSF-based co-pathology profile and the onset of MC along the disease course. Here, MAPT is linked to Parkinson disease.